Chlorhexidine

Prescription Peridex 0.12% oral rinse treats gingivitis as part of professional dental care between visits. It is not established therapy for acute necrotizing ulcerative gingivitis and its effect on periodontitis is not determined. Reduced gingival inflammation must not be used alone to rule out deeper periodontal disease.

OTC Hibiclens 4% skin cleanser reduces skin bacteria for labeled general/wound cleansing, handwashing/scrubbing and preoperative preparation. Prescription PerioChip 2.5 mg is placed professionally in periodontal pockets as an adjunct to scaling/root planing to reduce pocket depth in adult periodontitis. Neither indication authorizes swallowing the skin product or replacing periodontal procedures with a mouthwash.

This profile covers those three verified U.S. products. Chlorhexidine-alcohol applicators, impregnated devices, different mouthwash concentrations and other combination products require their own formulation-specific labels, drying/fire/device instructions and indications. The selected old PerioChip DailyMed record is not evidence of a newly revised 2026 label or current stock at a pharmacy.

After initial dental prophylaxis, swish 15 mL undiluted rinse for thirty seconds twice daily, morning/evening after toothbrushing, then spit out. Do not swallow, immediately eat, brush, or rinse with water/another mouthwash afterward. Arrange reevaluation/prophylaxis at intervals no longer than six months; duration otherwise follows the dentist’s plan.

For superficial wound/general cleansing, rinse with water, use the minimum amount needed, wash gently and rinse thoroughly. Healthcare handwash: about 5 mL, wash fifteen seconds then rinse/dry. Surgical hand scrub: about 5 mL with water/brush for three minutes, rinse, repeat and dry. Patient preoperative skin preparation: swab liberally for at least two minutes, dry with sterile towel and repeat. These are this selected cleanser’s directions, not an alcohol-applicator drying protocol.

One 2.5 mg chip per pocket with probing depth ≥ 5 mm; up to eight chips at one visit. Reassess/treat at three-month intervals if depth remains ≥ 5 mm. Clinician isolates/dries pocket and places the rounded end to maximum depth with forceps; the biodegradable chip needs no removal. If lost within forty-eight hours, the label advises replacement; after forty-eight hours, reevaluate at three months rather than automatically replace; ≥seven days is considered a full course. Notify the dentist rather than self-insert.

Peridex safety/effectiveness below eighteen and PerioChip pediatric use are not established. Hibiclens requires care in premature infants or infants below two months because irritation/chemical burns can occur. These labels provide no renal/hepatic reduction or dialysis dosing table; low measured dental absorption does not justify a systemic-use regimen.

Avoid the selected products with relevant chlorhexidine/ingredient hypersensitivity. Hibiclens also explicitly excludes head/face preoperative preparation, contact with meninges and genital use, and must stay out of eyes, ears and mouth. PerioChip’s formal contraindication is chlorhexidine sensitivity; an acutely abscessed pocket is unstudied and not recommended. These location restrictions are not universal permission to use another concentration there.

No boxed warning appears in these selected labels/Drug Facts. Serious allergy and route-specific tissue injury are still major warnings. The older chip label does not contain every later skin/dental product warning, so absence of a chip-specific anaphylaxis box is not proof that known allergy is safe.

Peridex can cause tooth/oral staining, calculus, altered taste, local irritation, allergy or mucosal symptoms; permanent taste alteration is rarely reported. Hibiclens can irritate/sensitize skin and cause infant chemical burns. PerioChip commonly causes temporary tooth/gingival sensitivity after scaling; infection/abscess reports require assessment. Dental trial symptoms should not all be presented as causally proven systemic reactions.

Peridex directions avoid immediate water/other mouthwash, brushing or food afterward; use after toothbrushing as labeled. Professional cleaning removes most stain/calculus, but some rough restorations can stain permanently. PerioChip patients avoid floss at treated sites for ten days while continuing other usual hygiene; no diet restriction is required. Do not apply the rinse’s after-dose eating restriction to the chip.

The selected labels contain no validated systemic CYP, anticoagulant or renal drug-interaction adjustment table. Tell clinicians about chlorhexidine allergy and all dental/skin products before procedures. Do not dilute/mix the skin cleanser with unverified preparations or assume alcohol-containing applicator compatibility from these labels. No universal twenty/thirty-minute toothpaste gap is invented.

Peridex below eighteen and PerioChip pediatric safety/effectiveness are unestablished; Hibiclens neonatal/young-infant use needs special care for burns. Older chip trial patients showed no identified overall difference, but numbers were insufficient to establish a separate response profile. Swallowing ability, dental conditions and caregiver technique matter individually.

Peridex and PerioChip advise pregnancy use only if clearly needed; relevant controlled human data are inadequate. Rinse human milk excretion is unknown and caution is advised. The reviewed chip label supplies no dedicated lactation recommendation; skin Drug Facts provides no pregnancy/lactation regimen. Do not substitute oral animal data for a guarantee about a periodontal route or presume absent infant exposure.

No numeric organ adjustment or dialysis algorithm is established. PerioChip periodontal management considers diabetes, cancer and immunocompromised status; pivotal studies excluded diabetic patients and acutely abscessed pockets were not studied. Professional review is required for significant disease rather than extend trial results to every population.

Chlorhexidine interacts with microbial surfaces and disrupts membranes/cellular contents. Rinse studies show reductions in sampled plaque bacteria, with uncertain relationship of microbiology to every clinical outcome. PerioChip releases drug locally while the matrix biodegrades; the chip’s proven role is adjunct pocket-depth reduction, not a universal systemic antibiotic effect.

About thirty percent of rinse active ingredient is retained orally and released gradually; GI absorption of swallowed chlorhexidine is poor but ingestion remains inappropriate. Chip release is variable; in-vitro release continues around 7–10 days and a small adult study detected no plasma/urine drug after four chips. Detection limits and route differences prevent claiming zero exposure in all patients. Skin Drug Facts supplies no validated product-specific half-life.

Dental use requires assessment of gums/periodontal pockets, plaque/calculus, staining/restorations, taste effects and pain/swelling. Peridex professional prophylaxis/review occurs at least every six months; chip pocket reassessment guides three-month retreatment. Skin use requires assessment of site, irritation, burn risk and proper rinse technique. These labels do not mandate a universal routine serum panel for local use.

Spit out oral rinse and keep skin cleanser external. Do not wear another product’s route instructions onto this one. For chip use, avoid floss at the site ten days, notify dentist if displaced and report significant pain/swelling. Stop and seek urgent help for serious allergy; contact Poison Control/medical help after accidental swallowing, especially with children or alcohol-containing rinse. Bring the exact package to assessment.

Selected Peridex is blue 0.12% oral rinse; 473 mL bottle NDC 48878-0620-1 with child-resistant cap. Selected Hibiclens is labeled 4% external skin cleanser. PerioChip is a small orange-brown rounded-end insert; selected twenty-chip carton NDC 52096-001-22. Match manufacturer/package and route; no tablet imprint is invented for these preparations.

Peridex: chlorhexidine gluconate 0.12% (1.2 mg/mL), with 11.6% alcohol. Hibiclens: 4% w/v chlorhexidine-gluconate solution for skin; it is not oral rinse. PerioChip: 2.5 mg chlorhexidine gluconate in biodegradable gelatin matrix, about 7.4 mg total chip mass and no preservative in selected panel. Other concentrations or alcohol applicators require separate verification.

Peridex: 20–25°C with 15–30°C excursions, dispensed in the provided bottle or amber glass. Hibiclens: 20–25°C; avoid heat above 40°C. PerioChip: 15–25°C in individual aluminum blister compartments, used professionally. Keep products out of children’s reach and follow package expiry; no universal after-opening discard period is supplied.